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Abstract
Background: Notch signalling is essential for the development and maintenance of the colonic
epithelium. Its inhibition induces a differentiation phenotype in vivo and reduces adenomas in
APCmin mice. Whether Notch signals are also required in colorectal cancer (CRC) has remained
elusive. Therefore, 64 CRC cell lines were analysed for the occurrence of proteolytically
processed, active Notch.
Results:  63 CRC lines contained a fragment with approximately the size of the Notch1
intracellular domain (NICD), which is required for signalling. Subsequent analyses with an antibody
that specifically recognises the free Val1744 residue generated by γ-secretase-mediated cleavage of
Notch1 showed that a subset of CRC cells lacks this specific Val1744-NICD. Surprisingly, inhibition
of Val1744-NICD signalling with different γ-secretase inhibitors (GSI) did not lead to substantial
effects on CRC cell line growth or survival. However, transient activation of Erk upon GSI
treatment was detected. Since cisplatin relies on Erk activation for bioactivity in some cells,
platinum compounds were tested together with GSI and enhanced cell killing in a subset of
Val1744-NICD-positive CRC cell lines was detected. Erk inhibition ablated this combination effect.
Conclusion: We conclude that γ-secretase inhibition results in activation of the MAP kinases
Erk1/2 and, when used in conjunction, enhances cell death induced by platinum compounds in a
large subset of colorectal cancer cell lines.
Furthermore the activation of Erk appears to be of particular importance in mediating the enhanced 
effect seen, as its inhibition abrogates the observed phenomenon. These findings do not only 
highlight the importance of signalling pathway crosstalk but they may also suggest a new avenue of 
combination therapy for some colorectal cancers.
Background
The Notch signalling pathway, already discovered in 1919
by Thomas H. Morgan in the fruit fly Drosophila mela-
nogaster, plays numerous roles in organismal develop-
ment and tissue homeostasis as well as in different cancers
[1-5]. For the activation of Notch signalling, a number of
proteolytic processing events are required, most notably
the final cleavage of Notch1 by a multi-protein complex
termed  γ-secretase. This releases a defined fragment
(Val1744-NICD) of the membrane bound Notch protein
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into the cytoplasm, from where it translocates into the
nucleus and subsequently mediates the transcription of
specific target genes by releasing the repressor activity of
CSL (CBF-1/Suppressor of Hairless [Su(H)]/LAG-1; [6]).
Recent reports have also documented the existence of
additional, 'non-canonical' Notch signalling pathways [7-
10].
It has been suggested that inhibition of Notch signalling,
for example by γ-secretase inhibition, may be a treatment
option for different types of cancers, including colorectal
adenocarcinomas (CRC) [7,11-14]. Notch inhibition in
normal colon epithelium induces premature differentia-
tion of proliferating cells and treatment of APCmin mice, a
mouse model of intestinal adenomas, with the potent γ-
secretase inhibitor (GSI) dibenzazepine (DBZ) reduces
adenomas [5]. However, it was not clear how important
Notch signalling is for malignant CRC.
In the current study it is shown that treatment of CRC cells
with γ-secretase inhibitors (GSI), which leads to inhibi-
tion of Notch signalling, is not sufficient to induce pro-
nounced inhibitory effects on CRC cell proliferation or
survival, but results in activation of the MAP kinases Erk1/
2. On the other hand, combination of GSI with platinum
compounds induced cell death in a substantial subset of




The GSI compounds DAPT (N- [N-(3,5-difluoropheny-
lacetyl-L-alanyl)]-S-phenylglycine t-butylester; γ-secretase
inhibitor IX; 565770) and DBZ [15] ((S, S)-2- [2-(3,5-dif-
luorophenyl)acetylamino]-N-(5-methyl-6-oxo-6,7-dihy-
dro-5H-dibenzo [b, d]azepin-7-yl)propionamide;
dibenzazepine;  γ-secretase inhibitor XX; 565789) were
purchased from Calbiochem (Darmstadt, Germany). The
GSI compound L-685,458 (1-benzyl-4-(1-(1-carbamoyl-
2-phenylethylcarbamoyl-3-methylbutylcarbamoyl)-2-
hydroxy-5-phenylpentyl)carbamic acid t-butylester;
L1790) was from Sigma-Aldrich (Poole, Dorset, UK).
Three platinum compounds cisplatin (232120; Calbio-
chem), carboplatin (C2538; Sigma-Aldrich) and oxalipla-
tin (Eloxatin 5 mg/ml, 248459; Sanofi Aventis, Frankfurt,
Germany) were used in this study. The Mek1/2 inhibitor
UO126 was from Cell Signaling Technology/NEB (9903;
Danvers, MA, USA)
Antibodies
Polyclonal anti-Notch1 (sc-6014-R) was from Santa Cruz
Biotechnology (Santa Cruz, CA, USA), anti-Notch1 mAb
(N6786) and anti-actin (A3853) from Sigma-Aldrich.
Anti-phospho-Erk1/2 (9101), anti-phospho-Akt (4051),
anti-Val1744-NICD (2421) and anti-cleaved PARP
(9546) was from Cell Signaling Technology. Anti-Bcl2
(B46620) was from Transduction Laboratories (Lexing-
ton, KY, USA). Peroxidase-conjugated anti-mouse (715-
036-151) or anti-rabbit IgG (711-036-152) antibodies
were from Jackson ImmunoResearch Laboratories (West
Grove, PA, USA). Anti-Hes1 was a gift from Dr. Tatsuo
Sudo, Toray Industries, Kamakura, Japan.
Cell lines, cell culture and lysis
The 64 human CRC cell lines used in this study are
derived from 63 different patients.
LS 174T and LS 180 originate from the same patient. A full
list of the cell lines with a description of their origins is
provided in the Additional file 1. For a further characteri-
sation of the 64 cell lines see also Emaduddin et al. [16].
The OXCO-1 and OXCO-3 lines were a gift from Khoon
Lin Ling and Vincenzo Cerundolo (WIMM, Oxford).
Cells were grown in Iscove's Modified Dulbecco's
Medium (IMDM) supplemented with 100 units/ml peni-
cillin, 100 μg/ml streptomycin and 10% (v/v) FBS at 37°C
in humidified atmosphere with 10% CO2. Prior to lysis,
cells were cultured for 48 h in an excess of medium unless
indicated otherwise.
For total cell lysis, cells were washed three times with
chilled PBS, lysed in a RIPA buffer (20 mM TrisHCl pH
7.5, 100 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.5%
deoxycholic acid, 0.1% SDS) supplemented with 2× Com-
plete™ protease inhibitor mix (11697498001; Roche
Diagnostics, Mannheim, Germany) and phosphatase
inhibitor cocktails 1 and 2 (P2850 and P5726; Sigma-
Aldrich) and scraped from the culture dishes. Lysates were
transferred to microfuge tubes, incubated at 4°C for 30
min on a nutator and then clarified by centrifugation at
22,000 × g for 30 min at 4°C. Protein concentrations were
determined by the Bradford method.
To obtain SDS lysates cells were washed three times with
PBS at room temperature, residual wash buffer was then
removed and cells were scraped with boiling SDS-PAGE
sample buffer, followed by 5 min boiling in a hot block.
After cooling to room temperature, lysates were sonicated
to fragment high molecular weight DNA.
SDS-PAGE, immunoblotting and immunoprecipitations
Lysates were size-separated by SDS-PAGE and transferred
to PVDF membrane (Hybond-P; GE Healthcare, Little
Chalfont, Buckinghamshire, UK). Membranes were
blocked with 5% skimmed dry milk or 5% BSA dissolved
in TBST (20 mM TrisHCl pH 7.5, 100 mM NaCl, 0.1%
Tween 20) as suggested by the antibody manufacturer and
incubated with primary antibody overnight at 4°C on a
nutator. Membranes were then washed 3–4 times for 10–Cell Communication and Signaling 2008, 6:8 http://www.biosignaling.com/content/6/1/8
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15 min with TBST and incubated for 1 h at room temper-
ature with peroxidase-conjugated anti-mouse or anti-rab-
bit IgG secondary antibodies. The signals were visualized
using ECL detection reagent (32106; Pierce/ThermoScien-
tific, Rockford, IL, USA). Immunoprecipitations were car-
ried out with 1 mg of total cell RIPA lysate using
polyclonal anti-NICD. Immunoprecipitates were sub-
jected to immunoblotting analysis with the anti-NICD
mAb.
Cell fractionation
Cells were washed twice with chilled PBS and once with
chilled hypotonic lysis buffer (HLB; 10 mM TrisHCl pH
7.5, 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 2 mM MgCl2,
1 mM DTT, and protease and phosphatase inhibitors as
detailed above). Cells were then scraped with 500 μl HLB,
transferrred into a pre-chilled dounce homogeniser and
incubated on ice for 15 min. The swollen cells were
dounce homogenised with 30 strokes of a tight fitting pes-
tle and the homogenate centrifuged at 1000 × g for 15 min
at 4°C. The pellet (P1; contains nuclei) was lysed in RIPA
buffer with inhibitors, cleared by centrifugation at 10 000
× g for 30 min at 4°C and the supernatants analysed by
immunoblotting (Additional file 2). The supernatant (S1)
that remained from the first centrifugation step was fur-
ther centrifuged at 100 000 × g for 30 min and the super-
natant representing the soluble protein fraction (S100)
and the pellet (P100) were collected. P100 was lysed in
RIPA buffer with inhibitors.
Cell treatment with compounds
To block γ-secretase, cells were initially treated for 48 h
with three different γ-secretase inhibitors, L-685,458,
DAPT and DBZ, at concentrations of 5 μM, 10 μM and
300 nM, respectively. Subsequently, to determine whether
prolonged inhibition of γ-secretase leads to any visible
effects on cell phenotype, treatment was performed for
more than a week with daily changes of medium contain-
ing inhibitor.
For combination treatment of cells with γ-secretase inhib-
itor and platinum compounds, DBZ was used for 48 h at
300 nM concentration combined with 1, 3 or 10 μM of
cisplatin, oxaliplatin or carboplatin. Cisplatin and carbo-
platin were always freshly dissolved in DMSO as they are
only moderately stable in solution. To block the Mek/Erk
pathway, cells were pre-treated with 30 μM of the Mek
inhibitor UO126 for 1 h, before further addition of 300
nM DBZ and 10 μM cisplatin for 48 h. Effects on cell
growth, survival or morphology were initially analysed by
light microscopy (Nikon Eclipse TS100 microscope) and
observed changes documented by digital imaging. To ana-
lyse changes in cell mass upon drug treatment, cells were
fixed and stained with crystal violet solution (0.1% crystal
violet in 50% methanol) for 20 min, then washed exten-
sively with water and air-dried. Protein-bound dye was
then extracted with 10% acetic acid and the OD of this
solution measured at 570 nm.
Results
Size heterogeneity of Notch fragments in CRC cells
To gain insight into potential functions of Notch signal-
ling in CRC cells, initially a panel of 64 CRC cell lines (fur-
ther details in Additional file 1) was analysed with an
antibody raised against the C-terminus of Notch1 for the
presence of a Notch fragment corresponding in size to the
Notch1 intracellular domain (NICD), which is generated
by γ-secretase cleavage of Notch. With this antibody, 63 of
64 CRC lines showed one or more bands corresponding
approximately to the expected size. As an example, the
results from 16 CRC lines are shown in Figure 1A. The
only exception found was the CRC line HDC-9, which was
also examined by subcellular fractionation, but no NICD
was detected (data not shown).
The other CRC lines differ in their level of NICD expres-
sion. In addition, some size heterogeneity of the detected
Notch fragments was obvious (Figure 1A). Since the NICD
is derived through proteolytic processing, it was impor-
tant to ensure that signals obtained were not artificially
introduced during the experimental procedure as a result
of incompletely inhibited proteases. To this end, protein
extracts were generated by lysing CRC lines with boiling
SDS-PAGE sample buffer (S) and comparing these to
lysates obtained with a RIPA-type buffer (R) that con-
tained high concentrations of protease inhibitors. Both
types of extracts showed very similar patterns of NICD
bands (see Figure 1B for results from 4 of 20 CRC lines
tested in total), indicating to us that insufficient protease
inhibition does not explain the observed NICD size heter-
ogeneity.
To exclude non-specific signals resulting from antibody
cross-reactivity, the NICD was immunoprecipitated using
a polyclonal NICD antibody and analysed by immunob-
lotting with an anti-NICD mAb after protein separation
by an extended SDS-PAGE run. As shown in Figure 1C,
this confirmed the considerable size heterogeneity of
NICD fragments detectable in the CRC lines, possibly a
consequence of deregulated proteases in these carcinoma
cells.
The γ-secretase-generated Notch fragment Val1744-NICD 
is detectable in a subset of CRC cells
As some of the NICD fragments detected in CRC may not
be functional, the presence of γ-secretase-cleaved, active
Val1744-NICD fragments was investigated. Western blot-
ting with a Val1744-NICD fragment-specific antibody
showed that approximately half of the CRC lines tested
have detectable levels of Val1744-NICD in total cellCell Communication and Signaling 2008, 6:8 http://www.biosignaling.com/content/6/1/8
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extracts (see Figure 2, upper panel for examples). How-
ever, some of the CRC cell lines that appear to be negative
in this experiment still show positive signals for Val1744-
NICD after subcellular fractionation in nuclear extracts
(see Additional file 2 for details of cell lines analysed).
Strikingly, expression of one of the primary Notch target
genes, Hes1, does not correlate with the abundance of the
Val1744-NICD fragment, suggesting that Notch pathway
activity may only fully drive Hes1 expression in some CRC
lines and that other pathways could contribute to Hes1
expression regulation in certain CRC cells (Figure 2, sec-
ond panel from top). On the other hand, very low
amounts of Val1744-NICD may be sufficient to drive
Hes1 expression in CRC lines. A direct comparison of the
obtained Val1744-NICD signals with a short exposure of
a blot using the same cell lysates but probed with the anti-
body raised against the C-terminal region of Notch indi-
cates an imperfect correlation of both Notch-directed
antibodies (see for example HT55 cells), again highlight-
ing the importance of determining the presence of
Val1744-NICD, which is able to translocate to the nucleus
and to induce signalling. Notably, even with the frag-
Expression level and size heterogeneity of Notch fragments detected in CRC cells Figure 1 (see previous page)
Expression level and size heterogeneity of Notch fragments detected in CRC cells. A Western blot detection of 
Notch fragments in total cell RIPA lysates. 100 μg of total cell protein extracts were subjected to SDS-PAGE and immunoblot-
ting to determine the abundance and sizes of C-terminal fragments of Notch1 (NICD). Results from 16 CRC lines are shown. 
The heterogeneity in the level of NICD expression and the presence of several NICD fragments of variable length is notable. B 
Comparison of NICD bands obtained with total cell RIPA lysates (R) and lysates obtained by harvesting cells with boiling SDS-
PAGE sample buffer (S). 20 CRC lines were analysed in total. Results from 4 CRC lines are shown as an example. Both protein 
extraction methods result in very similar NICD band patterns. C Size heterogeneity of immunoprecipitated NICD fragments. 
NICD fragments were precipitated with a polyclonal antibody (sc-6014-R) directed against the C-terminus of Notch1 and, 
after extended SDS-PAGE on a large 7% gel, immunoblotted with a mouse mAb (N6786) directed against an epitope in the 
cdc10-NCR region of Notch1.
Variable expression of γ-secretase-cleaved, active Notch1 (Val 1744-NICD) in CRC cells Figure 2
Variable expression of γ-secretase-cleaved, active Notch1 (Val 1744-NICD) in CRC cells. 100 μg of total cell RIPA 
lysates were analysed by immunoblotting using anti-Val1744-NICD antibody. Data from 16 cell lines are shown as an example 
(upper panel). Lysates were also analysed with anti-Hes1 to determine the expression of this well known Notch1 primary tar-
get (second panel from top). A short exposure of a western blot with an antibody directed against the C-terminus of Notch1 
reveals that the Val1744-NICD fragment is not always the most prominent fragment present in CRC cells (third panel from 










































































































97Cell Communication and Signaling 2008, 6:8 http://www.biosignaling.com/content/6/1/8
Page 6 of 13
(page number not for citation purposes)
ment-specific Val1744-NICD antibody more than one
protein band is detected in some CRC cell lines (for exam-
ple in LS123 and NCI-H747). Whether these bands are,
for example, due to differential protein modifications
remains to be determined. Taken together, these results
indicate a great degree of heterogeneity in the Notch frag-
ments present in different CRC cells.
γ-secretase inhibitors do not elicit striking effects on CRC 
cell line growth or survival
A primary aim of this study was to determine if Notch sig-
nalling is essential for CRC cells. Therefore, in a next step,
the potential roles of Notch signalling in CRC cells were
investigated in 12 cell lines by inhibiting γ-secretase
(Table 1). Nine of these lines detectably expressed
Val1744-NICD, albeit in three lines the γ-secretase specific
fragment was only detected upon cell fractionation (HCA-
7, HCA-46, LoVo; see also Additional file 2). Three CRC
lines did not express detectable levels of Val1744-NICD
(HDC-9, HDC-57, HDC-73), even after subcellular frac-
tionation.
To recognise potential inhibitor off-target effects, three
well characterised and structurally distinct GSI, namely
DAPT, L-685,458 and DBZ, were directly compared. These
were applied in concentrations typically used in the liter-
ature (see Table 1 for details) and proven to affect Hes1
expression within CRC cells in initial experiments (data
not shown). Cells were treated for 48 h and the detection
of prominent effects on cell proliferation, cell survival or
cell morphology attempted by light microscopy and cell
counting. Surprisingly, inhibition of Notch signalling did
not lead to substantial effects on CRC cell growth, mor-
phology or survival with DAPT and DBZ (data not
shown). In the case of the L-685,458 inhibitor com-
pound, a moderate degree of cell death was observed in 2
of the 12 CRC lines tested (CCK-81, VACO 4A). However,
as all compounds are known to elicit γ-secretase inhibi-
tion and DBZ is by far the most potent compound of the
three inhibitors tested, the two cell deaths seen upon
application of L-685,458 are very likely non-specific, off-
target effects. Light microscopic analyses of CRC cells were
subsequently continued for over a week, with daily addi-
tion of new medium and inhibitor, but without any
apparent effect on cell viability, growth or morphology.
Some cell lines were also analysed by soft agar colony for-
mation assay over a period of three weeks, again with no
obvious effect of GSI application (data not shown).
γ-secretase inhibition suppresses Hes1 expression and 
induces Erk activation
The molecular effects of γ-secretase inhibition were then
studied in more detail using the Val1744-NICD-positive
cell line CCK-81 and comparing DBZ, which is active in
nanomolar concentrations and preferentially affects
colonic epithelial cells in vivo [15] and the somewhat less
potent L-685,458 inhibitor over a time course of 48 h.
DAPT appeared to be the least potent of the three inhibi-
tors in first experiments (data not shown) and was not
used further.
As expected, treatment with either compound substan-
tially reduced the abundance of the Val1744-NICD frag-
ment within a few hours, albeit the effect with DBZ
Table 1: Effects of γ-secretase inhibitors and cisplatin on a panel of CRC cell lines
CRC line Val1744-NICD DAPT 10 μM L-685,458 5 μM DBZ 300 nM Cisplatin cell death (20 
μM,48 h)
CP+DBZ combi effect CD 
(48 h)
C80 + - - - + +
Caco-2 + - - - + +
CCK-81 + - CD - (+) (+)
CC07 + - - - + +
HCA-7 + (N) - - - + ++(24 h)
HCA-46 + (N) - - - (+) +
HDC-9 - - - - + -
HDC-57 - - - - - -
HDC-73 - - - - + -
LoVo + (N) - - - + (+)
LS123 + - - - + -
VACO 4A + - CD - - -
CD = cell death visible by light microscopy
CP = cisplatin
CP+DBZ = combination treatment with 10 μM CP and 300 nM DBZ
DAPT = N- [N-(3,5-Difluorophenacetyl-L-alanyl)]-S-phenylglycine t-butyl ester
DBZ = (S, S)-2- [2-(3,5-Difluorophenyl)acetylamino]-N-(5-methyl-6-oxo-6,7-dihydro-5H-dibenzo [b, d]azepin-7-yl)propionamide
(N) = Val1744-NICD detected in nuclear fraction after cell fractionation
NICD = Notch1 intracellular domain
- (minus symbol) = no visible effect on proliferation, cell death or cell morphologyCell Communication and Signaling 2008, 6:8 http://www.biosignaling.com/content/6/1/8
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appears to be more pronounced and persistent (Figure 3).
However, only a small effect was detected on the cleavage
of the caspase substrate poly (ADP-ribose) polymerase
(PARP; [17,18]), an indicator of cell death, with 48 h of
DBZ treatment, while L-685,458 induced a more rapid
response. Erk, a central player in the mitogenic pathway
[19,20], and Akt, a well-known cell survival regulator
[21], were phosphorylated on key regulatory epitopes
(Erk pT202/pY204; Akt pS473) upon treatment of CCK-
81 cells with either GSI. Bcl-2, a widely studied, anti-apop-
totic protein [22] was moderately reduced in both cases
(Figure 3). Erk phosphorylation on the crucial, activity-
regulating epitope T202/Y204 was also found repeatedly
with other CRC lines analysed, although the kinetics were
variable (data for HCA-7 cells shown in Additional file 3).
These results prove that, although GSI treatment of CRC
cells alone is not sufficient to induce major changes in cell
growth or survival, GSI still affect multiple proteins
involved in the regulation of these biological functions.
A review of the literature subsequently indicated that
some of the molecular effects elicited by GSI in CRC cells
could potentially modify the efficacy of existing anti-can-
cer drugs. For example, it has been reported that the chem-
otherapeutic drugs like cisplatin and carboplatin depend
on Erk activity for their pro-apoptotic effects, since inhibi-
tion of Mek/Erk signalling prevented cell death [23-28].
On the other hand, several reports support a different role
of Erk in certain types of cancer, associating its activity
with enhanced cancer cell survival [29-32].
To determine if GSI can modulate the activity of platinum
compounds in CRC cells, DBZ was combined with cispla-
tin, carboplatin or oxaliplatin in further analyses. All of
these compounds are currently in use in the therapy of
advanced CRC, but unfortunately none of them is potent
enough to cure a substantial number of patients, thus
clearly highlighting the urgent need for substantially
improved therapies for this frequent cancer type.
Molecular effects of γ-secretase inhibition on signalling proteins involved in regulating cell growth or death Figure 3
Molecular effects of γ-secretase inhibition on signalling proteins involved in regulating cell growth or death. 
CCK-81 cells were either left untreated (0), treated with DMSO as a control (DM) or incubated with the γ-secretase inhibitors 
as indicated. Cells were lysed in RIPA buffer and 50 μg of total protein was subjected to immunoblotting analysis as specified. 
Both inhibitors result in the down-regulation of Val1744-NICD, which is paralleled by a loss of Hes1 expression, an effect that 
is evident already after 3 to 6 h. Cleaved PARP, an indicator of cell death, was also analysed and more prominent with L-
685,458, which induces cell killing in CCK-81 by an unknown mechanism (Table 1). With both GSI, an increase in pErk 
(pT202pY204) and pAkt (pS473) is evident. In addition, a downregulation of anti-apoptotic Bcl-2 protein was detectable, to a 
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Induction of cell death by combination of GSI and 
platinum compounds in CRC cells
Different CRC cell lines were first treated with increasing
concentrations of cisplatin to establish at what doses cis-
platin substantially affects cell survival. While 3 μM cispl-
atin for 48 h showed typically little effect, cell death was
observed with 10 μM cisplatin in many CRC lines, so this
dose was used for further drug combination studies.
Results from HCA-7 cells are shown here as an example.
As readily shown in earlier experiments, application of
300 nM DBZ had no detectable effect on cell survival, but
combining 10 μM cisplatin with 300 nM DBZ led to mas-
sive cell death (Figure 4). This combination treatment was
applied to a total of 20 CRC lines, to determine how fre-
quently an effect can be detected. The results are summa-
rised in Tables 1 and 2. 3 of the 20 CRC lines (HDC-57,
COLO 320DM, VACO 4A) appeared to be resistant to cis-
platin and no effect of combination treatment with cispl-
atin and DBZ was seen in these lines. Of the remaining 17
cisplatin-sensitive cell lines, 10 showed at least some
degree of increased cell death (Tables 1 and 2), indicating
that a major subset of CRC lines is sensitive against the
combination of GSI and cisplatin. The effects of inhibitor
treatments were also quantified by crystal violet staining
of cells. Results are shown in Additional file 4.
All 4 CRC lines that lack detectable Val17744-NICD
expression (DLD-1, HDC-9, HDC-57, HDC-73) did not
show a cell killing effect upon drug combination, a find-
ing compatible with the hypothesis that inhibition of an
active Notch signalling pathway is required for the cell
killing effect of DBZ applied together with cisplatin. If this
would be correct, introduction of an exogenous Val1744-
NICD fragment, which should be unaffected by GSI, into
CRC cells, would abolish the combination effect of DBZ
and cisplatin treatment obtained with the parental cells.
Since transient transfection of CRC cells was only success-
ful for a small percentage of the total CRC cell population
in all CRC lines studied, we tried to further test this
hypothesis by attempting permanent expression of the
Val1744-NICD fragment, but failed so far to obtain clones
that stably expressed this Notch fragment. Therefore, we
are currently unable to formally exclude that a γ-secretase
target other than Notch is linked to the observed drug
combination-induced cell killing.
In addition to cisplatin, other platinum derivatives, in
particular carboplatin and oxaliplatin are widely used in
treating cancer patients. For example, a combination ther-
apy of oxaliplatin with other chemotherapeutic drugs (5-
fluorouracil, leucovorin) is now commonly used for treat-
ment of advanced CRC [33]. None of these regimens are,
however, even close to being curative for the majority of
patients, leaving much room for improved drug combina-
tions.
To detect a potential functional interplay of carboplatin or
oxaliplatin with GSI, 5 CRC lines were tested for the
effects of combination treatment with 300 nM DBZ and
these platinum compounds (10 μM). In HCT 116, HCA-7
and HCA-46 cells drug combination effects were
observed. By contrast, the Caco-2 and CC07 cell lines,
despite being well responsive to the combination of DBZ
and cisplatin, showed no effect with the other two plati-
num compounds (data not shown). These results were
somewhat unexpected, since cisplatin and carboplatin are
considered to be quite similar to each other with respect
to their mechanism of action and toxicity profile, while
oxaliplatin differs considerably with respect to these
parameters [34,35]. Clearly, more detailed studies are
needed to gain better insight into the differential effects of
combining GSI with different platinum compounds.
Inhibition of Erk activity suppresses cell killing induced by 
combining of DBZ with cisplatin
The observed Erk activation in CRC cells by GSI could be
a bystander effect that is not functionally linked to the cell
killing effect observed upon combination of GSI and plat-
inum compounds. In that case, suppression of Erk activity
may not quench the observed cell death induced by treat-
ment of cells with cisplatin and DBZ. However, preincu-
bation of HCA-7 cells with the Mek inhibitor UO126,
which leads to a reduction of active (pT202pY204) Erk,
prior to application of DBZ and cisplatin, clearly reduced
Table 2: Effects of DBZ and cisplatin on 8 additional CRC cell lines
CRC line Val1744-NICD DBZ 300 nM Cisplatin cell death (20 μM,48 h) CP+DBZ combi effect CD (48 h)
COLO 320DM + (N) - - -
COLO 741 + (N) - + +
DLD-1 - - (+) -
HCT 116 + (N) - + +
RCM-1 + - + (+) (72 h)
RKO + - + (+) (72 h)
SNU-C2B + - (+) -
SW620 + - + -
For details on abbreviations see footnote in Table 1Cell Communication and Signaling 2008, 6:8 http://www.biosignaling.com/content/6/1/8
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the number of killed cells (Figure 5). A reduced cleavage
of PARP was also evident when cells were pre-treated with
UO126 before the addition of DBZ and cisplatin. This
suggests that Mek-Erk signalling plays a functional role in
mediating CRC cell killing by combination of GSI and
platinum drugs.
Discussion
Until now, most patients with solid tumors that survive
their disease are cured through surgery, often in combina-
tion with radiation and/or chemotherapy. Cure rates are
especially high for patients with early stage disease.
Advanced tumors are in many cases at best delayed in
their progression through the use of chemotherapy and/or
molecularly targeted drugs. A range of novel molecularly
targeted drugs, for example acting against the EGF and IGF
Combination of Cisplatin with DBZ, a potent GSI, elicits a striking induction of cell death Figure 4
Combination of Cisplatin with DBZ, a potent GSI, elicits a striking induction of cell death. Cells were treated as 
indicated and digital images recorded (20× objective). 10 μM Cisplatin (CP) alone leads to a moderate degree of cell death. 
Note that less cells are present in cultures treated with cisplatin (upper left panel) compared to untreated or DBZ treated cul-
tures (upper right panel). The cells appear flatter and the nuclei larger. A section of the plate was chosen where only few dead 
cells obstruct the view onto the remaining cells (see Figure 5 for a lower magnification view of CP treated cells). The combina-
tion of cisplatin with DBZ leads to massive cell death.
HCA-7, 10 PM CP    48 h
HCA-7, 10 PM CP + 300 nM DBZ    48 h
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receptor families or other tyrosine kinase receptors, PI3
kinase (p110), Akt, mTor, the Wnt pathway, c-Met, Src,
CDKs or Aurora kinase are currently in pre-clinical and
clinical development [36-38]. However, like most of their
predecessors, many of these drug candidates are unfortu-
nately likely to fail, due to a lack of bioactivity and/or
dose-limiting adverse effects. Increasing the potency of
anti-tumor drugs while limiting their general toxicity
therefore remains a very important goal for cancer
research.
Platinum compounds are widely used tools in the arsenal
of oncologists and currently applied in approximately half
of all tumor therapies worldwide. Although cisplatin is
one of the few anticancer agents with real curative poten-
tial, leading to cure rates beyond 90% in testicular germ
cell cancer, its use in CRC has only been moderately suc-
cessful so far, primarily due to its dose-limiting toxicity.
Reducing the overall toxicity of platinum compounds
while maintaining or increasing their potency against
tumor cells is no easy task. Tumor-specific activation of
platinum compounds, although an attractive hypothetical
possibility and an active area of research [39], clearly still
has a long way to go before it will potentially become a
part of the clinical therapy repertoire.
Inhibition of Erk activation suppresses cell death induced by combining cisplatin and GSI Figure 5
Inhibition of Erk activation suppresses cell death induced by combining cisplatin and GSI. Cells were treated as in 
Figure 4, or additionally pre-incubated for 1 h with the Mek inhibitor UO126 (30 μM) where indicated and digital images 
recorded (10× objective). Cells were harvested after 24 h and equal amounts of RIPA lysates (50 μg) analysed for pErk and 
cleaved PARP as before. UO126 blocks the induction of pErk by DBZ and cisplatin, reduces the level of cleaved PARP and sup-
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An alternative route to a better usage of existing and newly
introduced anti-cancer compounds might be their
rational combination with other drugs, based on the indi-
vidual, patient-specific effects they elicit on the molecular
signalling machinery in cancer cells. Again, this is no easy
task, but numerous tools and a wealth of molecular
knowledge about signalling pathways have been gathered
by researchers over the last decades.
The data presented here suggest to us that inhibition of γ-
secretase, which abrogates signals from the Notch path-
way, could possibly potentiate the in vivo bioactivity of
standard chemotherapeutic drugs used in the therapy of
colorectal carcinomas and potentially some other cancers.
It seems likely to us that the observed cell killing activity
elicited by GSI in combination with platinum compounds
is not due to a simple overall enhancement of toxicity
through drug combination, but that it is cell type-specific
instead. Previous studies with the highly potent inhibitor
compound DBZ in healthy mice have shown a preferen-
tial effect of DBZ on colonic epithelial cells [15]. The DBZ
resistance of some colorectal cancer cells that are sensitive
to cisplatin would also seem to argue against a general cell
toxicity effect and for a more specific combination effect
limited to a molecular 'subtype' of CRC. Combining GSI
and platinum compounds may therefore create a novel
therapeutic window for the treatment of some colorectal
cancers.
Whilst there are insufficient data until now to postulate a
synergistic effect of DBZ and cisplatin, this intriguing pos-
sibility warrants further investigation. Furthermore,
despite our encouraging findings with cultured cells,
future studies in animal models as well as additional anal-
yses of other platinum compounds and other anti-cancer
drugs are clearly needed to decide which drug combina-
tions should be taken forward into clinical testing.
Importantly, this may not be the same combination of
drugs for different molecular subtypes of CRCs. At
present, it is often impossible to estimate how an individ-
ual patient's tumor will respond to a certain therapy. One
way to overcome this limitation in the future could be to
test primary cancer cells obtained from biopsies, surgery
or potentially even tumor cells isolated from patient
blood [40] for responses to GSI and platinum com-
pounds. The GSI inhibitor MK-0752 has already shown
some activity in T-cell ALL, which frequently harbor muta-
tions in Notch. GSI inhibitors are also currently being
tested in breast, CNS and other cancers [41] (further info
at http://clinicaltrials.gov). This provides valuable infor-
mation on their toxicity, pharmacokinetic and pharmaco-
dynamic properties. Nevertheless, the molecular effects
on signalling pathways induced by GSI are only partially
known and how Erk activation is induced in CRC cells
remains unclear.
In this study, inhibition of Erk was achieved by using the
well-characterised Mek inhibitor UO126. Direct selective
inhibition of Erk with small molecules is currently proba-
bly not feasible since Erk inhibitors typically show spill-
over effects onto CDKs, that are, like Erks, proline-directed
kinases with considerable similarity in their catalytic
clefts.
Previously, links between Notch and the Ras-Mek-Erk
pathway have been described in different systems. For
example, Notch1 has been described as a target of onco-
genic Ras in fibroblasts and Notch inhibition suppressed
Ras mediated tumorogenicity in mice [42]. By contrast,
mouse mammary tumors resulting from activated Notch4
show activated Mek and Akt and a synergistic relationship
between Notch and the Ras signalling pathway has been
proposed [43]. In small cell lung cancer cells, overexpres-
sion of active Notch1 or 2 led to an increase in Erk activa-
tion [44]. From these results it is obvious that very
different signalling flows exist between Notch and Erks,
which depend, at least in part, on the cell type investi-
gated. Additional analyses are required to determine how
GSI increase pErk and pAkt in CRC cells.
As of now, it is not certain that Notch1 is the, or even a,
key target mediating GSI effects seen in CRC. A number of
other γ-secretase substrates are known, including the sig-
nalling proteins ErbB4 [45], IGF1R [46], E-Cadherin and
DCC [47]. Expression of active Notch1 fragments in sev-
eral CRC lines by using viral vectors should be able to
shed some light onto this open question rather quickly.
Conclusion
The results presented here once again highlight the molec-
ular diversity of lesions in cancer cells originating from the
same tissue and suggest that the combination of GSI with
platinum compounds may provide an option to improve
treatments for a subset of CRC patients.
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